z-logo
open-access-imgOpen Access
Rare Case of Cryptococcal Meningitis in Non-HIV Patient with Mantle Cell Lymphoma Associated with Acalabrutinib (Tyrosine Kinase Inhibitor)
Author(s) -
Trivedi Krunal,
AUTHOR_ID,
Kinjal D. Patel,
AUTHOR_ID
Publication year - 2022
Publication title -
journal of infectious diseases and case reports
Language(s) - English
Resource type - Journals
ISSN - 2634-8861
DOI - 10.47363/jidscr/2022(3)153
Subject(s) - mantle cell lymphoma , ibrutinib , medicine , immunosuppression , cryptococcus , cryptococcosis , lymphoma , cryptococcus neoformans , immunology , chronic lymphocytic leukemia , leukemia , biology , genetics , microbiology and biotechnology
Cryptococcus neoformans infections are more common among immunosuppressed individuals, causing the most widespread opportunistic CNS infection among HIV-positive patients [1]. Specifically, those with cellular immunosuppression, such as patients with HIV positive CD4 counts less than 100. When a patient presents with atypical symptoms, it can be difficult to diagnose due to its infrequent presentation in HIV negative patients. Due to the rarity of encounters in HIV-negative patients, when atypical symptoms are present, it poses a diagnostic challenge. Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin B-cell lymphoma that is known to be associated with cellular immunosuppression [2]. This demonstrates the need for early diagnosis and recognition of cryptococcal infections and as a physician should be vigilant to diagnose cryptococcal who is on Acalabrutinib with MCL [3]. CLL patients receiving ibrutinib should be evaluated for cryptococcal infection, which is potentially life threatening if overlooked [4]. Meningitis caused by Cryptococcus mainly presents with fever and altered mental status but in this case, our patient 78-year-old male with mantle cell lymphoma, undergoing a regimen of Rituximab-Bendamustine (BR) in combination with acalabrutinib (TKI), presented with hypotension to ED in June 2021. Cryptococcal infection in patient receiving ibrutinib were mostly reported in patients with Chronic lymphocytic leukemia, who have poor immune reconstitution. Here we are reporting case of cryptococcal meningoencephalitis in patient with MCL on acalabrutinib which is never reported before.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here